CEL-SCI Corp. (CVM) - Price to Earnings Ratio

CEL-SCI Corporation (CVM) develops immunotherapies to combat head and neck tumors, and the price trend for this asset on GURU.Markets currently stands at -0.90. A cohesive team of scientists dedicated to achieving a scientific breakthrough is working on the project; however, the business relies on dwindling reserves due to high R&D expenses in the absence of profit.

CEL-SCI Corporation revenues depend on the successful market launch of the immunotherapy drug Multikine for the treatment of head and neck oncology. By analyzing the company's normalized P/E, an investor assesses the ratio of current market capitalization to net income, which allows for determining the premium paid for the future commercialization potential of biotechnological developments and estimating the investment payback period.